MA33810B1 - Compositions pour traiter les nausées et vomissements à médiation centrale - Google Patents

Compositions pour traiter les nausées et vomissements à médiation centrale

Info

Publication number
MA33810B1
MA33810B1 MA34953A MA34953A MA33810B1 MA 33810 B1 MA33810 B1 MA 33810B1 MA 34953 A MA34953 A MA 34953A MA 34953 A MA34953 A MA 34953A MA 33810 B1 MA33810 B1 MA 33810B1
Authority
MA
Morocco
Prior art keywords
vomiting
compositions
treating nausea
central mediation
nausea
Prior art date
Application number
MA34953A
Other languages
Arabic (ar)
English (en)
Inventor
Fabio Trento
Sergio Cantoreggi
Giorgia Rossi
Roberta Cannella
Daniele Bonadeo
Riccardo Braglia
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43608757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33810(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of MA33810B1 publication Critical patent/MA33810B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Paints Or Removers (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des compositions et des procédés permettant de traiter et prévenir les nausées et vomissements dans le cas de patients traités par chimiothérapie, par radiothérapie, ou par chirurgie.
MA34953A 2009-11-18 2012-06-11 Compositions pour traiter les nausées et vomissements à médiation centrale MA33810B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26247009P 2009-11-18 2009-11-18
US38270910P 2010-09-14 2010-09-14
PCT/IB2010/003106 WO2011061622A1 (fr) 2009-11-18 2010-11-18 Compositions pour traiter les nausées et vomissements à médiation centrale

Publications (1)

Publication Number Publication Date
MA33810B1 true MA33810B1 (fr) 2012-12-03

Family

ID=43608757

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34953A MA33810B1 (fr) 2009-11-18 2012-06-11 Compositions pour traiter les nausées et vomissements à médiation centrale

Country Status (40)

Country Link
US (1) US12042494B2 (fr)
EP (3) EP2727590B1 (fr)
JP (1) JP5890780B2 (fr)
KR (1) KR101615108B1 (fr)
CN (6) CN106421793B (fr)
AP (1) AP3083A (fr)
AU (1) AU2010320598B2 (fr)
BR (1) BR112012011485B1 (fr)
CA (1) CA2778301C (fr)
CL (1) CL2012001276A1 (fr)
CO (1) CO6551693A2 (fr)
CR (1) CR20120216A (fr)
CU (1) CU24048B1 (fr)
CY (1) CY1118062T1 (fr)
DK (2) DK2361090T3 (fr)
DO (1) DOP2012000138A (fr)
EA (1) EA026815B1 (fr)
EC (1) ECSP12011907A (fr)
ES (4) ES2623503T3 (fr)
GE (1) GEP20156226B (fr)
GT (1) GT201200156A (fr)
HK (2) HK1214148A1 (fr)
HR (3) HRP20140759T1 (fr)
HU (1) HUE029677T2 (fr)
IL (1) IL219576A (fr)
LT (1) LT2722045T (fr)
MA (1) MA33810B1 (fr)
MX (1) MX2012005347A (fr)
MY (1) MY159393A (fr)
NI (1) NI201200090A (fr)
NZ (1) NZ599439A (fr)
PE (1) PE20121483A1 (fr)
PH (1) PH12012500887A1 (fr)
PL (3) PL2361090T3 (fr)
PT (2) PT2361090E (fr)
RS (2) RS55206B1 (fr)
SI (2) SI2361090T1 (fr)
SM (1) SMT201400112B (fr)
TN (1) TN2012000170A1 (fr)
WO (1) WO2011061622A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2623503T3 (es) 2009-11-18 2017-07-11 Helsinn Healthcare Sa Composiciones para tratar náuseas y vómitos mediados centralmente
EP2722045B1 (fr) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions pour traiter les nausées et vomissements à médiation centrale
WO2013004766A1 (fr) * 2011-07-04 2013-01-10 Ferrari Giulio Antagonistes des récepteurs nk-1 pour traiter une néovascularisation cornéenne
CN105412110B (zh) * 2011-10-18 2018-05-25 赫尔森保健股份公司 奈妥匹坦和帕洛诺司琼的治疗性组合
US8426450B1 (en) * 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
US9403772B2 (en) 2011-11-29 2016-08-02 Helsinn Healthcare Sa 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
CN103520725B (zh) * 2012-07-05 2017-10-24 海思科医药集团股份有限公司 一种治疗呕吐的药物组合物
ES2824552T3 (es) 2015-03-04 2021-05-12 Vanda Pharmaceuticals Inc Método de tratamiento con tradipitant
CN106902086B (zh) * 2015-12-23 2020-10-20 江苏恒瑞医药股份有限公司 一种包含奈妥匹坦的固体组合物
GB201618425D0 (en) * 2016-11-01 2016-12-14 Acacia Pharma Ltd method
GB201702250D0 (en) 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
CN108721214B (zh) * 2017-04-14 2020-06-16 和龙 奈妥吡坦和帕洛诺司琼复方纳米粒溶液、纳米粒及制备方法和用途
CN108853010A (zh) * 2017-05-15 2018-11-23 和龙 奈妥吡坦环糊精包合物、复方组合制剂及其制备方法和用途
CN109200018A (zh) * 2017-07-04 2019-01-15 南京诺瑞特医药科技有限公司 含有奈妥吡坦的微乳制剂
CN119074729A (zh) * 2017-11-17 2024-12-06 万达制药公司 使用川地匹坦治疗胃肠疾病的方法
EP3746078A4 (fr) * 2018-02-02 2021-11-17 Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) Formulations orales et utilisations de celles-ci
AU2021407138A1 (en) * 2020-12-25 2023-06-29 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Use of nk1 antagonist prodrug compound in combination with 5-ht3 receptor antagonist
EP4385500A1 (fr) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Combinaison de doses fixes comprenant du nétupitant et du palonosétron
WO2024126398A1 (fr) 2022-12-12 2024-06-20 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Combinaison de doses fixes comprenant du netupitant et du palonosétron
EP4633608A1 (fr) 2022-12-12 2025-10-22 Alfred E. Tiefenbacher (GmbH & Co. KG) Association de dose fixe sans antioxydant de netupitant et de palonosétron
EP4385497A1 (fr) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Combinaison de doses fixes sans antioxydant de nétupitant et de palonosétron
WO2025246530A1 (fr) * 2024-05-30 2025-12-04 The Chinese University Of Hong Kong Traitement anti-émétique personnalisé pour nausées et vomissements induits par chimiothérapie

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL166267B1 (pl) 1989-11-28 1995-04-28 Syntex Inc Sposób wytwarzania nowych zwiazków trójpierscieniowych PL PL PL PL
US5510486A (en) 1994-07-26 1996-04-23 Syntex (U.S.A.) Inc. Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one
US6297395B1 (en) 1995-11-10 2001-10-02 The Secretary Of State For Defence In Her Brittanic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Calixarenes and their use for sequestration of metals
PT1035115E (pt) 1999-02-24 2005-01-31 Hoffmann La Roche Derivados de 4-fenilpiridina e a sua utilizacao como antagonistas do receptor nk-1
MXPA03000366A (es) 2000-07-14 2003-05-27 Hoffmann La Roche N-oxidos como profarmacos antagonistas del receptor nk1 de derivados de 4-fenil-piridina.
JP4116436B2 (ja) 2000-12-14 2008-07-09 エフ．ホフマン−ラ ロシュ アーゲー 自己乳化脂質マトリックス（ｓｅｌｍ）
DE10393729T5 (de) 2002-11-15 2005-10-13 Helsinn Healthcare S.A. Verfahren zur Behandlung von Emesis
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
MY143789A (en) 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
MXPA05010819A (es) * 2003-04-08 2006-03-30 Progenics Pharm Inc Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
KR20070094666A (ko) 2005-02-25 2007-09-20 에프. 호프만-라 로슈 아게 약제 물질 분산성이 향상된 정제
US7479312B2 (en) 2005-07-07 2009-01-20 Konica Minolta Opto, Inc. Retardation film, polarizing plate, and liquid crystal display device
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007096763A2 (fr) 2006-02-23 2007-08-30 Pfizer Limited Pipéridinoylpyrrolidines en tant qu'agonistes du récepteur de la mélanocortine de type 4
KR101441459B1 (ko) 2006-10-24 2014-09-18 헬신 헬쓰케어 에스.에이. 안정성 및 생체이용률이 개선된 염산 팔로노세트론을 포함하는 연질 캡슐
US20110014117A1 (en) * 2007-06-28 2011-01-20 Schering Corporation Anti-igf1r
JP2011505873A (ja) * 2007-12-18 2011-03-03 シェーリング コーポレイション 抗ｉｇｆ１ｒ療法に対する感受性のバイオマーカー
ES2623503T3 (es) 2009-11-18 2017-07-11 Helsinn Healthcare Sa Composiciones para tratar náuseas y vómitos mediados centralmente

Also Published As

Publication number Publication date
AU2010320598B2 (en) 2016-06-16
PT2361090E (pt) 2014-09-03
ES2623503T3 (es) 2017-07-11
CN106512010A (zh) 2017-03-22
EP2727590B1 (fr) 2015-10-21
CN106421793A (zh) 2017-02-22
HUE029677T2 (hu) 2017-03-28
AP2012006278A0 (en) 2012-06-30
HK1214148A1 (zh) 2016-07-22
SI2722045T1 (sl) 2017-02-28
MY159393A (en) 2016-12-30
ECSP12011907A (es) 2012-10-30
EA026815B1 (ru) 2017-05-31
DOP2012000138A (es) 2012-11-15
PT2722045T (pt) 2016-10-18
EP2361090A1 (fr) 2011-08-31
AU2010320598A1 (en) 2012-06-14
CN106421793B (zh) 2023-06-16
ES2595077T3 (es) 2016-12-27
US12042494B2 (en) 2024-07-23
RS55206B1 (sr) 2017-01-31
GEP20156226B (en) 2015-01-26
IL219576A0 (en) 2012-06-28
CN102655864A (zh) 2012-09-05
CU24048B1 (es) 2014-12-26
IL219576A (en) 2017-08-31
WO2011061622A1 (fr) 2011-05-26
ES2494015T3 (es) 2014-09-12
PL2722044T3 (pl) 2017-08-31
DK2361090T3 (da) 2014-08-25
DK2722045T3 (en) 2016-10-24
LT2722045T (lt) 2016-09-26
PL2722045T3 (pl) 2017-03-31
PL2361090T3 (pl) 2014-10-31
PE20121483A1 (es) 2012-12-02
HRP20140759T1 (hr) 2014-10-24
CA2778301A1 (fr) 2011-05-26
CA2778301C (fr) 2016-06-14
CO6551693A2 (es) 2012-10-31
CL2012001276A1 (es) 2012-12-07
HRP20161277T1 (hr) 2016-11-18
BR112012011485B1 (pt) 2021-06-29
EP2722044A1 (fr) 2014-04-23
MX2012005347A (es) 2012-08-03
RS53491B1 (sr) 2015-02-27
CN107050455A (zh) 2017-08-18
JP5890780B2 (ja) 2016-03-22
EP2727590A1 (fr) 2014-05-07
KR20120101456A (ko) 2012-09-13
JP2013511507A (ja) 2013-04-04
GT201200156A (es) 2014-03-27
CR20120216A (es) 2012-07-24
KR101615108B1 (ko) 2016-05-12
CU20120078A7 (es) 2012-10-15
BR112012011485A2 (pt) 2018-04-03
CN107050455B (zh) 2020-09-29
SI2361090T1 (sl) 2014-09-30
AP3083A (en) 2015-01-31
PH12012500887A1 (en) 2016-08-26
CN104856998A (zh) 2015-08-26
EP2722044B1 (fr) 2017-01-04
EA201290356A1 (ru) 2012-12-28
ES2559475T3 (es) 2016-02-12
NZ599439A (en) 2014-06-27
HK1214147A1 (zh) 2016-07-22
CN104856999A (zh) 2015-08-26
SMT201400112B (it) 2014-11-10
CY1118062T1 (el) 2017-06-28
TN2012000170A1 (en) 2013-12-12
US20230263799A1 (en) 2023-08-24
HRP20170419T1 (hr) 2017-06-02
NI201200090A (es) 2012-11-13
EP2361090B1 (fr) 2014-05-21

Similar Documents

Publication Publication Date Title
MA33810B1 (fr) Compositions pour traiter les nausées et vomissements à médiation centrale
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
TN2009000529A1 (en) Methods and compositions for treating allergic diseases
EP2493464A4 (fr) Méthylsulfonylméthane (msm) pour le traitement de micro-organismes résistants aux médicaments
MX368173B (es) Una composición farmacéutica que comprende una proteína de fusión actriia-fc expresada de células cho.
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
TW200736275A (en) Methods and compositions for treating allergic diseases
UA107783C2 (en) Isoindoline compounds for use in treating cancer
NZ708928A (en) Mannose derivatives for treating bacterial infections
IN2012DN02471A (fr)
MX349886B (es) Moleculas de union anti-pseudomonas lectina pisum satinum (psl) y usos de las mismas.
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
EA201200428A1 (ru) Композиция и способ для лечения ожирения
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
EP2597949A4 (fr) Compositions submicroniques
WO2012024670A3 (fr) Composition et méthodes de traitement du glioblastome
MX2010009697A (es) Tratamientos anticancerigenos mejorados.
MX337145B (es) Composiciones farmaceuticas.
CY1115904T1 (el) Συνθεσεις και μεθοδοι για την προληψη και τη θεραπεια του βακτηριακου καψιματος
CY1115471T1 (el) Συνθεσεις για την αντιμετωπιση της ναυτιας και του εμετου κεντρικης προελευσης